Standalone and Consolidated Financial Result for the Half year and year ended on March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Trident Lifeline Ltd submitted its audited financial results for FY 2024-25 on 28th April 2025, along with the appointment of a new internal auditor. On a standalone basis, total income rose to Rs 7,757.14 lacs from Rs 4,685.52 lacs (up ~66% YoY), driven by net sales of Rs 6,719.91 lacs vs Rs 4,465.24 lacs. Standalone net profit jumped to Rs 1,305.14 lacs from Rs 704.34 lacs (up ~85% YoY), with basic EPS rising to Rs 11.35 from Rs 6.23. On a consolidated basis (which now includes five subsidiaries — TNS Pharma, TLL Parenterals, TLL Herbal, TLL Elements, and Trident Mediquip, acquired during FY 2024), total income reached Rs 9,519.58 lacs and net profit came in at Rs 1,049.48 lacs (up ~77% YoY), with EPS of Rs 10.22. Statutory auditor A Bafna & Associates issued an unmodified opinion. The company also appointed DAC & Co. as the new internal auditor for FY 2025-26.
Strong double-digit growth in both revenue and profits, with the consolidated picture boosted by newly acquired subsidiaries, suggests improving business momentum for shareholders. The unmodified audit opinion and absence of any going-concern or qualification flags is reassuring, though investors should note the change in consolidation method (from proportionate to equity method) and that the company is on BSE's SME platform.